Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO

ClinicalTrials.gov lists FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO as lead sponsor of 219 trials. It has 107 active development programs and 25 approved assets.

IT Hospital Manufacturer
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

41 0 2003 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 17 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 23 in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.

Logo Monica Cremonesi, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.

This page covers FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO: 219 lead-sponsored trials and 2 legal-entity registrations. The parent company on record for FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO is Istituti di Ricovero e Cura a Carattere Scientifico, which does not have its own page on this site.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (266)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Trials by start year as sponsor or collaborator (23)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 17
2025 28
2024 24
2023 41
2022 34
2021 30
2020 24
2019 17
2018 16
2017 11

Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 90 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (107)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Trimethoprim / Sulfamethoxazole Vesico-Ureteral Reflux Phase 3 1
Amoxicillin-Potassium Clavulanate Combination Vesico-Ureteral Reflux Phase 3 1
L-arginine and liposomal vitamin C Heart Failure Phase 3 1
Amoxicillin-Potassium Clavulanate Combination Renal Insufficiency, Chronic Phase 3 1
Trimethoprim / Sulfamethoxazole Renal Insufficiency, Chronic Phase 3 1

Approved assets (25)

Shown in this order: max phase first.

Approved assets
Drug Trials
Diclofenac 1
Plasma-derived FVIII/VWF concentrate 1
ultra-micronized palmitoylethanolamide 1
Diet 1
Lurasidone 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
74% hit target (n=38) 46% on time (n=39)

Manufacturing and distribution sites (1)

Manufacturing and distribution sites
Facility Location Regulators Member organization
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, IT EMA

Biomarker capability evidence (251)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
AATF Trial sponsor Named in trial inclusion criteria
ACE Trial collaborator Named in trial inclusion criteria
ADAMTS13 Trial sponsor Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.

Counted at group level under Istituti di Ricovero e Cura a Carattere Scientifico: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.